Cost Utility Analysis of Infliixmab and Adalimumab Compared with Conventional Therapy in Patients with Crohn Disease in the Islamic Republic of Iran
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.3042
https://www.valueinhealthjournal.com/article/S1098-3015(17)33377-6/fulltext
Title :
Cost Utility Analysis of Infliixmab and Adalimumab Compared with Conventional Therapy in Patients with Crohn Disease in the Islamic Republic of Iran
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)33377-6&doi=10.1016/j.jval.2017.08.3042
First page :
A636
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1289